Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.31 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.31 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3174371 | 0.81 | DGAT1 (0.38) | DGAT1PKMKEAP1NFE2L2HCAR2 | |
| SCHEMBL28248746 | 0.79 | — | — | |
| SCHEMBL28697421 | 0.79 | DGAT1 (0.41) | DGAT1 | |
| SCHEMBL631049 | 0.79 | CYP2C19 (0.38) | DGAT1PKMTSHRMAPT | |
| SCHEMBL12138536 | 0.78 | DGAT1 (0.34) | DGAT1PKMKEAP1NFE2L2HCAR2 | |
| SCHEMBL30343873 | 0.78 | DGAT1 (0.34) | DGAT1KEAP1NFE2L2HCAR2TSHR | |
| Ammonia Solution, Strong SCHEMBL16895224 | 0.77 | CYP2C19 (0.37) | DGAT1MAPT | |
| SCHEMBL4548467 | 0.77 | CYP4F2 (0.48) | PKMHCAR2TSHRMAPT | |
| SCHEMBL27478465 | 0.77 | DGAT1 (0.35) | DGAT1TSHR | |
| SCHEMBL1114586 | 0.77 | MAPK1 (0.41) | DGAT1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171463-A1 | EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF | BIOGEN MA INC. | 2025-05-29 | — | — | US | disclosed |
| CN-119654330-A | STING agonist compounds | 苏特罗生物制药公司 | 2025-03-18 | — | — | CN | disclosed |
| US-20230339915-A1 | MODULATORS OF ALPHA-1 ANTITRYPSIN | VERTEX PHARMACEUTICALS INCORPORATED | 2023-10-26 | — | — | US | disclosed |
| US-20230339915-A1 | MODULATORS OF ALPHA-1 ANTITRYPSIN | VERTEX PHARMACEUTICALS INCORPORATED | 2023-10-26 | — | — | US | disclosed |
| CN-111971277-B | Benzothiophenes and related compounds as STING agonists | 默沙东有限责任公司 | 2023-06-06 | — | — | CN | disclosed |
| CN-108064224-B | Amide-substituted thiazoles as modulators of Ror gamma t | 詹森药业有限公司 | 2022-03-29 | — | — | CN | disclosed |
| CN-111971277-A | Benzothiophenes and related compounds as STING agonists | 默沙东公司 | 2020-11-20 | — | — | CN | disclosed |
| EP-2534132-B1 | SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDES | HOFFMANN LA ROCHE (CH) | 2017-04-26 | — | — | EP | disclosed |
| CN-102159207-B | Substituted pyrrolidine-2-carboxamides | HOFFMANN LA ROCHE | 2015-02-04 | — | — | CN | disclosed |
| CN-102753522-B | Substituted pyrrolidine-2-carboxamides | HOFFMANN LA ROCHE | 2013-11-27 | — | — | CN | disclosed |
| WO-2009073818-A1 | COMPOUNDS AND THERAPEUTIC USE THEREOF | MYRIAD GENETICS, INC. (US) | 2009-06-11 | — | — | WO | disclosed |
| US-7504508-B2 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-7498436-B2 | Substituted hydroxyethylamines | PHARMACIA & UPJOHN COMPANY LLC (US) | 2009-03-03 | — | — | US | disclosed |
| US-20070213407-A1 | Compounds to treat Alzheimer's disease | ELAN PHARMACEUTICALS AND PHARMACIA & UPJOHN COMPANY LLC | 2007-09-13 | — | — | US | disclosed |
| CN-101018770-A | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARM INC (US) | 2007-08-15 | — | — | CN | disclosed |
| EP-1740547-A1 | PGD2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-01-10 | — | — | EP | disclosed |
| CN-1816531-A | Process for the preparation of aryl alkyl acid derivatives and their use for the treatment of obesity | BAYER PHARMACEUTICALS CORP (US) | 2006-08-09 | — | — | CN | disclosed |
| US-20060106256-A1 | Substituted hydroxyethylamines | PHARMACIA & UPJOHN COMPANY | 2006-05-18 | — | — | US | disclosed |
| US-20050256158-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. | 2005-11-17 | — | — | US | disclosed |
| WO-2005100321-A1 | PGD2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256158-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | PTGDR2, LTB4R2, CYSLTR2 | DGAT1 829/4885PKM 4094/4885KEAP1 837/4885 |
| US-20070213407-A1 | Compounds to treat Alzheimer's disease | PSEN2, PSEN1, CHAT | DGAT1 1650/4885PKM 1631/4885KEAP1 272/4885 |
| US-20250171463-A1 | EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF | EBPL, EBP, CREBBP | DGAT1 2382/4885PKM 2891/4885KEAP1 640/4885 |
| US-20230339915-A1 | MODULATORS OF ALPHA-1 ANTITRYPSIN | SERPINA2, SERPINA3, SERPINB1 | DGAT1 1027/4885PKM 3753/4885KEAP1 564/4885 |
| US-20060106256-A1 | Substituted hydroxyethylamines | HNMT, PNMT, BCHE | DGAT1 2308/4885PKM 865/4885KEAP1 1264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.